Fennec Pharmaceuticals (FENC)

• Market cap: $244M
• 1 day: -2.99%
• 5 days: -3.2%
• 1 month: -5.19%
• 3 months: 5.29%
• 6 months: 34.77%
• Year to date: 39.27%
• 1 year: 62.52%
• 5 years: 50.52%
• 10 years: -27%
• Sector: Healthcare
• Industry: Biotechnology

About: Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Employees: 32

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

150% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 6

38% more capital invested

Capital invested by funds: $81.6M [Q1] → $113M (+$31.3M) [Q2]

13% more funds holding

Funds holding: 68 [Q1] → 77 (+9) [Q2]

4% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 24

0.74% more ownership

Funds ownership: 48.53% [Q1] → 49.28% (+0.74%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $13
• Avg. target: $13.5
• High target: $14

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju	$13	Buy Reiterated	21 Aug 2025
Craig-Hallum Chase Knickerbocker	$14	Buy Maintained	15 Aug 2025